These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 38660145)

  • 1. Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights.
    López-Castro R; Fuentes-Martín Á; Medina Del Valle A; García Peña T; Soro García J; López González L; Cilleruelo Ramos Á
    Open Respir Arch; 2024; 6(3):100323. PubMed ID: 38660145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
    Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
    EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma.
    Jang HJ; Truong CY; Lo EM; Holmes HM; Ramos D; Ramineni M; Lee JS; Wang DY; Pietropaolo M; Ripley RT; Burt BM; Lee HS
    Ann Thorac Surg; 2022 Nov; 114(5):1842-1852. PubMed ID: 34592265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.
    Gray SG
    BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tsunami of immunotherapy reaches mesothelioma.
    Mielgo-Rubio X; Cardeña Gutiérrez A; Sotelo Peña V; Sánchez Becerra MV; González López AM; Rosero A; Trujillo-Reyes JC; Couñago F
    World J Clin Oncol; 2022 Apr; 13(4):267-275. PubMed ID: 35582652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
    Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
    Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.
    Reveneau MF; Masliah-Planchon J; Fernandez M; Ouikene A; Dron B; Dadamessi I; Dayen C; Golmard L; Chauffert B
    Front Oncol; 2024; 14():1410322. PubMed ID: 39091916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
    Hylebos M; Van Camp G; van Meerbeeck JP; Op de Beeck K
    J Thorac Oncol; 2016 Oct; 11(10):1615-26. PubMed ID: 27282309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition.
    Cantini L; Laniado I; Murthy V; Sterman D; Aerts JGJV
    Lung Cancer; 2022 Mar; 165():91-101. PubMed ID: 35114509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma.
    Yun KM; Bazhenova L
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
    Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).
    Rijavec E; Biello F; Barletta G; Dellepiane C; Genova C
    Mol Clin Oncol; 2022 Apr; 16(4):89. PubMed ID: 35251640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
    Chi Y; Liu Y; Zhao J
    Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
    Tada A; Minami T; Kitai H; Higashiguchi Y; Tokuda M; Higashiyama T; Negi Y; Horio D; Nakajima Y; Otsuki T; Mikami K; Takahashi R; Nakamura A; Kitajima K; Ohmuraya M; Kuribayashi K; Kijima T
    Lung Cancer; 2023 Jun; 180():107219. PubMed ID: 37146474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma.
    Rondon L; Fu R; Patel MR
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
    Tolani B; Acevedo LA; Hoang NT; He B
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What's the place of immunotherapy in malignant mesothelioma treatments?
    Grégoire M
    Cell Adh Migr; 2010; 4(1):153-61. PubMed ID: 20179421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates in Management of Malignant Pleural Mesothelioma.
    John A; O'Sullivan H; Popat S
    Curr Treat Options Oncol; 2023 Dec; 24(12):1758-1789. PubMed ID: 37975977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
    BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.